Literature DB >> 3557314

Overnight salivary caffeine clearance: a liver function test suitable for routine use.

G Jost, A Wahlländer, U von Mandach, R Preisig.   

Abstract

The feasibility of measuring caffeine clearance from saliva (SCl) was assessed in ambulatory patients with liver disease and in a control group, and the results were compared with quantitative liver function tests. For this purpose, the subjects were given 280 mg caffeine p.o. in decaffeinated coffee powder between noon and 4 p.m., and caffeine concentrations were measured in saliva (using an enzyme immunoassay) before bedtime and upon arising. In the cirrhotics (n = 29), SCl was 0.58 +/- S.D. 0.45 ml per min X kg, thus being reduced to approximately one-third of drug-free, nonsmoking controls (1.53 +/- 0.46, n = 18); although patients with noncirrhotic liver disease showed intermediate values (0.95 +/- 0.47), their reduction in SCl was significant (p less than 0.001). SCl was correlated with indocyanine green fractional clearance, galactose elimination capacity and aminopyrine breath test; however, the closest relationship (Rs = 0.80) was observed with the aminopyrine breath test. It is suggested that the measurement of SCl represents a noninvasive and innocuous procedure for quantifying hepatic microsomal function, and is suitable for routine use. Since a.m. saliva concentrations of caffeine are highly correlated (Rs = -0.94) with SCl, further simplification of the test to a single-point measurement appears possible.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3557314     DOI: 10.1002/hep.1840070221

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  13 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  The role of salivary caffeine clearance in the diagnosis of chronic liver disease.

Authors:  Anurag Tripathi; Brijesh Tiwari; Ranjit Patil; Vikram Khanna; Vandana Singh
Journal:  J Oral Biol Craniofac Res       Date:  2015-01-23

4.  Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function.

Authors:  J E McDonagh; V V Nathan; I C Bonavia; G R Moyle; A R Tanner
Journal:  Gut       Date:  1991-06       Impact factor: 23.059

5.  Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism.

Authors:  H Wietholtz; T Zysset; K Kreiten; D Kohl; R Büchsel; S Matern
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

9.  Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.

Authors:  D Ullrich; D Compagnone; B Münch; A Brandes; H Hille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Salivary caffeine metabolic ratio in alcohol-dependent subjects.

Authors:  Veerapol Kukongviriyapan; Laddawan Senggunprai; Auemduan Prawan; Danu Gaysornsiri; Upa Kukongviriyapan; Jareerat Aiemsa-Ard
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.